By Fineline Cube 
Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) announced that it has entered into a license agreement with Yafei (Shanghai) Biomedical Technology Co., Ltd. and its subsidiary Affinity Biopharmaceutical Co., Ltd. The agreement grants Anglikang exclusive rights to research, develop, manufacture and commercialise the IMD‑1005 TMEAbody in China, including mainland, Hong Kong, Macau and Taiwan.
Deal Highlights
| Item | Detail |
|---|---|
| License Scope | Exclusive R&D, production & commercialization of IMD‑1005 in China |
| Upfront Payment | RMB 150 million paid in staged instalments to Yafei & Affinity |
| Milestone Payments | Up to RMB 620 million tied to R&D and sales milestones |
| Royalty | 12.8 % of net sales during the royalty period |
| Target | CD47‑targeting Tumour Micro‑Environment‑Activated Antibody (TMEAbody) |
About IMD‑1005
- Mechanism – Blocks CD47, a key “don’t‑eat‑me” signal, to enhance macrophage‑mediated tumour clearance.
- Innovation – First‑in‑class TMEAbody designed to activate within the tumour micro‑environment.
- Global Position – Developed by Affinity, a Yafei subsidiary, and the only CD47‑targeting TMEAbody currently in advanced clinical development.
Strategic Implications
- Market Expansion – Anglikang will be the sole manufacturer and distributor of IMD‑1005 across the Chinese market, positioning it as a leader in oncology therapeutics.
- Financial Upside – The RMB 620 M milestone budget and 12.8 % royalty structure provide a robust revenue pipeline once the product moves to market.
- Collaborative Synergy – The partnership leverages Yafei’s global R&D capabilities and Affinity’s clinical expertise, enhancing Anglikang’s product portfolio and pipeline depth.
Outlook
Anglikang plans to initiate pre‑clinical studies immediately under the new license, with a projected regulatory filing in 2027. The company’s management remains optimistic about the commercial prospects of IMD‑1005, citing its unique mechanism and the strong demand for CD47‑targeted therapies in China’s rapidly growing oncology market.-Fineline Info & Tech